Given their elevated expression in multiple cancers and prominent roles in extracellular acidification of the tumour microenvironment resulting in increasing metastatic potential and decreasing the efficacy of chemotherapy, CA9/CA12 specific inhibitors are currently emerging as potential anti-cancer drugs particularly for the treatment of solid cancers [37,38]. This evidence concerns the gene CA9 and neoplasm.